medigraphic.com

2001, Number S1

<< Back Next >>

Arch Cardiol Mex 2001; 71 (S1)

Converting enzyme inhibitors or AT1 angiotensin selective receptors blockers

Trevethan CS

Language: Spanish
References: 37
Page: 171-176
PDF size: 51.40 Kb.


ABSTRACT

The arrival of angiotensin converting enzyme inhibitors (ACE), and AT1 angiotensin selective receptors blockers, has changed the panorama of systemic high blood pressure and cardiac insuficiency treatments. These inhibitors and blockers have also been useful in cases of left asympthomatic ventricular dysfunction, myocardial infarction and post- infarction and various nephropathies- not only diabetes dependent but due to other etiologies as well. Furthermore, its application in primary prevention of coronary cardiopathies has satarted to become evident. The main advantages of this new group of drugs are their relative harmlessness and lesser undesirable side effects, as those caused by other antihipertensives agents. The AT1 receptor inhibitors of angiotensin have actually not proven to be superior than the ACE inhibitors (although the latter are not worse) but are better tolerated and protect a greater period of time with a single dosis. A greater number of macro studies with selective AT1 receptor blockers is necesary to know its right place in therapeutics.


REFERENCES

  1. BRUNNER HR, LARAGH JH, BAER L, ET AL: Essential hypertension: renin and aldosterone, heart attack and stroke. N Eng J Med 1972; 286: 441-9.

  2. YAMADA H, FABRIS B, ALLEN AM, JACKSON B, JOHNSTON CI, MENDELSON AO, ET AL: Localization of angiotensin-converting enzyme in the rat heart. Cir Res 1991; 68: 651-65.

  3. JOHNSTON CI, BURRELL LM, PERICH R, JANDELEIT K, JACKSON B: The tissue renin-angiotensin system and its functional rol. Clin Exper Pharmacol Physiol 1992;19:1-5.

  4. REGOLI D, BARABE J: Pharmacology of bradikinin and related kinins. Pharmacol Rev 1980; 32: 1-46.

  5. MEGARRY SG, SAPSFORD R, HALL AS, BALL SG: Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction? Drugs 1997; 54(suppl 5): 48-58.

  6. BOULANGER C, SCHINI VB, MONCADA S, VANHOUTTE PM: Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradikinin, adenosin diphosphate, calcium ionophore A 23187 and nitric oxide. Br J Pharmacol 1990; 101: 152-6.

  7. KOMAJDA M, WIMART MC: Angiotensin converting enzyme inhibition: from viper to patient. Heart 2000; 84: 11-14.

  8. Tight Blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.

  9. ANSSON L, LINDHOLM LH, NISKANEN L, LAUKE J, HEDNER T, NIKLASON A, ET AL: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-16.

  10. DALHLOF B, PENNERT K, HANSSON L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analisis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.

  11. HE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: results of the co-operative north Scandinavian ennalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.

  12. THE SOLV INVESTIGATORS: Effect of enapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.

  13. COHN JN, JOHNSON G, ZIESCHE S, COBB F, FRANCIS G, TRISTANI F, ET AL: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10

  14. THE ATLAS STUDY GROUP: Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinopril on morbidity and mortallity in chronic heart failure. Circulation 1999; 100: 2312-18.

  15. ISIS-4 COLLABORATIVE GROUP ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.

  16. GRUPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL´INFARTO MIOCARDICO. GISSI– 3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.

  17. PFEFFER MA, BRAUNVALD E, MOYE LA, BASTA L, BRAUN EDZH, KADDI TE, ET AL: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med 1992; 327: 669-77.

  18. LEWIS EJ, HUNSICKER LG, BRAIN RP, ROHDE RD: The effect of angiotensin-convertingenzime inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.

  19. THE EUCLID STUDY GROUP: Ramdomised placebo control led trial of lisinopril in normotensive patients with insulin dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.

  20. LOCATELLI F, CARBARNS IR, MASCHIO G, MANN JF, PONTICELLI C, RITZ E, ET AL: Long term progression of chronic renal insufficiency study group. Kidney Int Suppl 1997; 63: S63-6

  21. THE GISEN GROUP: Randomised placebocontrolled trial of the effect of ramipril on decline in glomerular filtration rate and risk ofterminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997; 349: 1857-63.

  22. ALBERG G, FERRER P: Effects of captopril on atherosclerosi in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15(Suppl): S65- S72.

  23. DAUGHERRY A, MANNING MW, CASSIS LA: Angiotensin II promotes Atherosclerotic lesions and aneurysms in apolipoprotein E deficient mice. J Clin Invest 2000; 105: 1605-12.

  24. HOPE: The Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 2000; 342: 145-53.

  25. WONG PC, HART SFD, TIMERMANS PB: Effect of angiotensin II antagonism on canine renal sympathetic nerve function. Hypertension 1991; 17: 1127-34.

  26. BUNKENBURG B, VAN AMELSVOORT T, ROGG H, WOOD JM: Receptor-mediated effects of angiotensin II on growth on vascular smooth muscle cells from spontaneusly hypertensive rats. Hypertension 1992; 20: 746-54.

  27. RIEGGER GA, BOUZO H, PETR P, MUNZ J, SPACE KR, PETHIG H, ET AL: Improvement in excercise tolerance and symptoms of congestive heart failure during treatmen with candesartan cilexetil. Symptom, Tolerance resoponse to excercise trial of candesartan cilexetil in heart failure. (STRETCH) investigators. Circulation 1999; 100: 2224-30.

  28. PITT B, SEGAL R, MARTINEZ FA, MEURERS G, COWLEY AJ, DEEDWANIA PC, ET AL: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.

  29. MCKELVIE RS, YUSUF S, DPHIL D, PERICAK D, AVEZUM A, BURNS RJ, ET AL: Comparison of candesartan, enalapril, and Their combination in Congestive Heart Failure. Randomized Evaluation of Strategies for left ventricular Dysfunction (RESOLVD) pilot study The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.

  30. PITT B, POOLE-WILSON PA, SEGAL R, MARTINEZ FA, DICKSTEIN K, CAMM AJ, ET AL: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE–II. Lancet 2000; 355: 1582-87.

  31. LACOUCIERE Y, BELANGER A, GODIN C, HALLE JP, ROSS S, WRIGHHT N, ET AL: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-9

  32. MANCIA G, ZANCHETTI A, AGABITI-ROSEI E, BENEMIO G, DE CEARIS R, FOGARI R, ET AL: Ambulatory Blood pressure is superior to clinic blood presure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE study group. Study on ambulatory monitoring of blood pressure and lisinopril evaluation. Circulation 1997; 95: 1464-70

  33. MEREDITH PA: ACE inhibition and AT1 receptor blockers: efficacy and duration in hypertension. Heart 2000; 84(Suppl 1): 39-41.

  34. LACOURCIERE Y, ASMAR R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo controlled forced titration study. Candesartan/losartan study investigators. Am J Hypertens 1999; 12: 1181-7.

  35. MALLION JM, LACOURCIERE Y: Telmisartan Blood Presssure Monitoring Group. A comparisson of the blood pressure profile of telmisartan and losartan at 18-24 hours post-dosing as measured by ambulatory blood pressure monitoring. Am J Hypertens 1998; 11: 262-264.

  36. LACOURCIERE Y, NEUTEL JM, SMITH TH: Twenty-four hour blood pressure monitoring to compare efficacy and duration of action of the AT1 telmisartan to amlodipine. Am J Hypertens 1997; 10: 7-12.

  37. HAMROFF G, KATZ SD, MANCINI D, BLAUFARB I, BIJOU R, PATEL R, ET AL: Addition of angiotensin II receptor blockade to maximal angiotensing-converting enzyme inhibition improves excercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2




2020     |     www.medigraphic.com